ImmunologybioRxiv
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
E. J. Pomeroy, J. T. Hunzeker, M. T. Kluesner…·B. S. Moriarity
This paper develops a CRISPR/Cas9-based method to edit human NK cells, enhancing their anti-cancer activity by knocking out ADAM17 and PD1.
DOI 10.1016/j.ymthe.2019.10.009